Core Viewpoint - Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into allegations against Keros Therapeutics, Inc. (KROS) and is encouraging investors to reach out for more information [1] Group 1 - The investigation is focused on potential misconduct or irregularities related to Keros Therapeutics, Inc. [1] - Investors are being urged to contact the firm for further details regarding the allegations [1]

Group 1 - The article discusses an active investigation regarding Keros Therapeutics, Inc. for investors who may have lost money on their investments [1] Group 2 - Investors are encouraged to contact Levi & Korsinsky for assistance related to their losses in Keros Therapeutics, Inc. [1]

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS ...

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012 ...

Core Viewpoint - Keros Therapeutics has voluntarily halted dosing in certain treatment arms of the TROPOS trial due to safety concerns related to adverse events observed in patients with pulmonary arterial hypertension [1][2] Group 1: Company Actions - The company announced a halt in dosing for the 3.0 mg/kg and 4.5 mg/kg treatment arms of the TROPOS trial while continuing with the 1.5 mg/kg arm after a safety review [1][2] - Keros is collaborating with the FDA and other regulatory authorities to address the safety concerns and has notified investigators about the decision [2] - The company expects to present topline data from all treatment arms in the TROPOS trial in the second quarter of 2025 [2] Group 2: Trial Information - The TROPOS trial is a Phase 2 clinical trial evaluating the efficacy of cibotercept in patients with pulmonary arterial hypertension [4] - The primary objective of the trial is to assess the effect of cibotercept on pulmonary hemodynamics compared to placebo [4] - The trial is fully enrolled, and the independent Data Monitoring Committee conducted a risk and benefit assessment prior to the dosing halt [2] Group 3: Product Information - Cibotercept is designed to inhibit TGF-β signaling, which is linked to smooth muscle hypertrophy and fibrosis, potentially treating conditions like pulmonary arterial hypertension [5] - The drug aims to enhance BMP signaling pathways, which are often reduced in patients with certain cardiovascular disorders [5]

Financial Performance - Keros reported a net loss of $53.0 million in Q3 2024, compared to a net loss of $39.4 million in Q3 2023, representing an increase of 34.3%[3] - Total revenue for Q3 2024 was $0.388 million, significantly higher than $0.008 million in Q3 2023, marking a 4,850% increase[10] - General and administrative expenses rose to $9.8 million in Q3 2024 from $9.1 million in Q3 2023, an increase of 7.7%[5] - Research and development expenses increased to $49.2 million in Q3 2024 from $34.1 million in Q3 2023, a rise of 44.3%[4] Cash Position - Cash and cash equivalents as of September 30, 2024, were $530.7 million, up from $331.1 million as of December 31, 2023, reflecting a 60.3% increase[6] - The company expects its cash position will fund operations into Q3 2027, supported by net proceeds from its at-the-market offering[2] Asset Growth - The total assets of Keros as of September 30, 2024, were $579.3 million, compared to $370.0 million as of December 31, 2023, an increase of 56.5%[11] Clinical Development - Keros completed enrollment ahead of schedule in its Phase 2 TROPOS trial of cibotercept (KER-012) for pulmonary arterial hypertension[2] Leadership Changes - Keros appointed Yung H. Chyung, M.D., as Chief Medical Officer effective November 1, 2024, indicating a strengthening of its executive leadership[2] Shareholder Information - The weighted-average common stock outstanding increased to 37,590,727 in Q3 2024 from 29,668,247 in Q3 2023, a growth of 26.7%[10]

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2024. “This continues to be ...

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...